Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Non Small Cell Lung Cancer
73%
Disease
55%
Small Cell Lung Cancer
51%
Cisplatin
42%
Lung Cancer
41%
Paclitaxel
41%
Neoplasm
40%
Small Cell Carcinoma
28%
Etoposide
23%
Malignant Neoplasm
22%
Cyclophosphamide
21%
Carboplatin
21%
Doxorubicin
19%
Gemcitabine
16%
Phase II Trials
16%
Remission
14%
Carcinoembryonic Antigen
14%
Survival Rate
12%
Methotrexate
12%
Iodine-131
11%
Epidermal Growth Factor Receptor
11%
Biological Marker
11%
Phase I Trials
11%
Immunotherapy
11%
Ifosfamide
10%
Anticarcinogen
10%
Topotecan
10%
Progression Free Survival
10%
Vincristine
10%
Overall Survival
10%
Clinical Trial
10%
Pharmacokinetics
9%
Soft Tissue Sarcoma
9%
Ferritin Antibody
9%
Pemetrexed
9%
Antiemetic Agent
8%
Chemoradiation Therapy
8%
Neutropenia
8%
Solid Malignant Neoplasm
8%
Carcinoma
7%
Leukopenia
7%
Nausea and Vomiting
7%
Maximum Tolerated Dose
7%
N Methylformamide
7%
Combination Therapy
7%
Liver Cell Carcinoma
7%
Adverse Event
7%
Vinorelbine
7%
Breast Cancer
6%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
84%
Chemotherapy
48%
NCCN Guidelines
32%
Lung Carcinoma
27%
Phase II Study
27%
Small Cell Carcinoma
27%
Eastern Cooperative Oncology Group
24%
Cisplatin
23%
Small Cell Lung Cancer
22%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Paclitaxel
19%
Oncology
19%
Response Rate
19%
Tumor
16%
Lung Cancer
16%
Radiation Therapy Oncology Group
15%
Median Survival
15%
Etoposide
15%
Partial Response
14%
Clinical Practice Guidelines
14%
Radiation Therapy
14%
Ifosfamide
13%
Phase II Trial
13%
Taxol
13%
Complete Response
11%
Gemcitabine
11%
Group Studies
11%
Cyclophosphamide
10%
Immune Checkpoint Inhibitors
10%
Phase I Study
10%
Soft Tissue Sarcoma
10%
Remission
10%
Lung Cancer Treatment
10%
Metastatic Non-small Cell Lung Cancer
9%
Iodine-131 (131I)
9%
Carboplatin
9%
Combination Chemotherapy
9%
Phase I Trial
9%
Leukopenia
9%
Lung Cancer Screening
8%
Immune Checkpoint Blockade
7%
Doxorubicin
7%
Thrombocytopenia
7%
NCCN Clinical Practice Guidelines
7%
Topotecan
7%
Antineoplastic Agents
7%
Carcinoembryonic Antigen
7%
Metastatic Disease
7%
Survival Rate
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
74%
Oncology
65%
Lung Cancer
55%
Neoplasm
43%
Radiation Therapy
42%
Disease
40%
Small Cell Lung Cancer
29%
Small-Cell Carcinoma
25%
Malignant Neoplasm
20%
Surgery
16%
Soft Tissue Sarcoma
15%
Biological Marker
14%
Doxorubicin
14%
Carcinoembryonic Antigen
13%
Paclitaxel
13%
Etoposide
13%
Epidermal Growth Factor Receptor
12%
Phase II Trials
11%
Overall Survival
11%
Cisplatin
11%
Metastatic Carcinoma
11%
Breast Cancer
10%
Lung Cancer Screening
10%
Adjuvant Chemotherapy
9%
Computer Assisted Tomography
8%
Immunotherapy
8%
Cyclophosphamide
8%
Diagnosis
8%
Neoadjuvant Chemotherapy
8%
Targeted Therapy
8%
Systemic Therapy
8%
Survival Rate
7%
Progression Free Survival
7%
Chemoradiotherapy
7%
Immune Checkpoint Inhibitor
7%
Cancer Therapy
6%
Carcinoma
6%
Carboplatin
6%
Lung Carcinoma
6%
Ovarian Cancer
6%
Chemotherapy
6%
Pneumonia
6%
Combination Chemotherapy
6%
Breast Disease
6%
Arm
5%
Clinical Trial
5%
Non-Small Cell Lung Cancer
5%
Vincristine
5%
Primary Tumor
5%
Group Trial
5%